Lisata Therapeutics, Inc.

NasdaqCM LSTA

Lisata Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -23.48 M

Lisata Therapeutics, Inc. Operating Income is USD -23.48 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 10.44% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Lisata Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -26.22 M, a 54.72% change year over year.
Lisata Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -57.91 M, a -109.46% change year over year.
Lisata Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -27.65 M, a -47.21% change year over year.
Lisata Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -18.78 M, a 0.13% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqCM: LSTA

Lisata Therapeutics, Inc.

CEO	Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
IPO Date	March 1, 1999
Location	United States
Headquarters	110 Allen Road
Employees	25
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Key trends

Past 5 years